(PharmaNewsWire.Com, June 09, 2017 ) Uterine fibroids are benign tumors that originate in the uterus (womb). Although they are composed of the same smooth muscle fibers as the uterine wall (myometrium), they are much denser than normal myometrium. Uterine fibroids are usually round. The most common symptoms of uterine fibroids include heavy menstrual bleeding, prolonged menstrual periods seven days or more of menstrual bleeding, pelvic pressure or pain, frequent urination, difficulty emptying your bladder, constipation and backache or leg pains.
Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Uterine Leiomyoma (Uterine Fibroids) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders) pipeline guide also reviews of key players involved in therapeutic development for Uterine Leiomyoma (Uterine Fibroids) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 4, 1, 4 and 3 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.
Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
- The pipeline guide provides a snapshot of the global therapeutic landscape of Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders). - The pipeline guide reviews pipeline therapeutics for Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Company profiles
AbbVie Inc Addex Therapeutics Ltd Bayer AG BioSpecifics Technologies Corp Dongkook Pharmaceutical Co Ltd Kissei Pharmaceutical Co Ltd Laboratoire HRA Pharma Ogeda SA Repros Therapeutics Inc Takeda Pharmaceutical Company Ltd
Number of Products under Development for Uterine Leiomyoma (Uterine Fibroids), H1 2017 Number of Products under Development by Companies, H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 Products under Development by Companies, H1 2017 Products under Development by Universities/Institutes, H1 2017 Number of Products by Stage and Target, H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Uterine Leiomyoma (Uterine Fibroids) - Pipeline by AbbVie Inc, H1 2017 Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Addex Therapeutics Ltd, H1 2017 Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Bayer AG, H1 2017 Uterine Leiomyoma (Uterine Fibroids) - Pipeline by BioSpecifics Technologies Corp, H1 2017 Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Dongkook Pharmaceutical Co Ltd, H1 2017 Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Kissei Pharmaceutical Co Ltd, H1 2017 Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Laboratoire HRA Pharma, H1 2017 Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Ogeda SA, H1 2017 Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Repros Therapeutics Inc, H1 2017 Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017 Uterine Leiomyoma (Uterine Fibroids) - Dormant Projects, H1 2017 Uterine Leiomyoma (Uterine Fibroids) - Discontinued Products, H1 2017
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
